Hologic price target lowered to $45 from $48 at Piper Jaffray

Piper Jaffray analyst William Quirk lowered his price target for Hologic to $45 while keeping an Overweight rating on the shares following the company’s fiscal Q4 results. Outside of the Cynosure recalls, the other businesses had solid quarters and third party seller checks support the Cynosure recovery story, Quirk tells investors in a post-earnings research note. The analyst, however, took his estimates to the very low end of management’s guidance and believes investors “can be patient on their entry point.”
https://thefly.com/landingPageNews.php?id=2820159